Related Experiment Videos
Fragile sites and bladder cancer
Helen Therese Moriarty1, Lucy Robyn Webster
1School of Biomedical Sciences, Faculty of Health Studies, Charles Sturt University, Wagga Wagga 2678, Australia. hmoriarty@csu.edu.au
Cancer Genetics and Cytogenetics
|March 21, 2003
Summary
Chromosomal fragile sites are linked to bladder cancer development. Over half of bladder cancer rearrangements occur at fragile sites, many near cancer-associated genes.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Environmentally induced chromosomal fragile sites have been associated with cancer.
- Chromosomal alterations are frequently observed in bladder cancer.
Purpose of the Study:
- To investigate the potential relationship between fragile sites and chromosomal alterations in bladder cancer.
- To determine if specific fragile sites are disproportionately represented in bladder cancer genomic rearrangements.
Main Methods:
- Literature review of current studies on bladder cancer and chromosomal fragile sites.
- Analysis of reported chromosomal rearrangements in bladder cancer.
- Identification of fragile sites overlapping with cancer-associated genes.
Main Results:
- 56% of chromosomal rearrangements in bladder cancer were located at recognized fragile sites (OR = 6.88).
- 65% of identified fragile sites were implicated in bladder cancer.
- 55% of implicated fragile sites overlapped with cancer-associated genes (oncogenes, tumor suppressors, etc.).
- Commonly implicated fragile sites include FRA1D, FRA1F, FRA8C, FRA9D, FRA9E, and FRA11C.
Conclusions:
- A significant correlation exists between fragile sites and chromosomal alterations in bladder cancer.
- Fragile site expression may contribute to the genetic damage leading to bladder cancer development.
- These findings suggest specific genetic damage profiles associated with fragile sites in bladder cancer etiology.